Asset
TALETRECTINIB
NUVATION BIO INC. CLASS A COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06564324 | phase3 | recruiting | 2024-11-27 | 2029-01-01 | Nuvation Bio Inc. | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients |
| NCT05357820 | phase1 | completed | 2021-07-19 | 2021-12-03 | Nuvation Bio Inc. | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK |
| NCT04395677 | phase2 | active_not_recruiting | 2020-07-07 | 2024-06-07 | Nuvation Bio Inc. | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene |
| NCT05357911 | phase1 | completed | 2021-07-13 | 2021-08-20 | Nuvation Bio Inc. | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin |
| NCT07154706 | phase3 | recruiting | 2025-08-21 | 2030-08-30 | Nuvation Bio Inc. | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) |
FDA applications (0)
This company has no applications containing this asset.